Affymax to complete Hematide Phase 3 clinical study by the final end of 2009 Affymax.

And European countries, including two trials in individuals on dialysis and two trials in patients not really on dialysis. The trials in non-dialysis sufferers, called PEARL 1 and PEARL 2, are analyzing the safety and efficacy of Hematide in comparison to darbepoetin alfa in correcting anemia and keeping hemoglobin levels over time. In dialysis individuals, the trials, called EMERALD 1 and EMERALD 2, are analyzing the safety and efficacy of Hematide and its own ability to maintain hemoglobin amounts in the target range when individuals are switched from epoetin alfa or epoetin beta to Hematide. Analysis of efficacy for every study is founded on assessments of non-inferiority to the comparator drugs. The principal efficacy endpoint is the mean alter in hemoglobin from baseline. The hemoglobin target range is 11-12 g/dL for studies in non-dialysis individuals and 10-12 g/dL for research in dialysis sufferers.The results, which also recommend therapeutic interventions to ease long-lasting pain, are reported in The EMBO Journal. Chronic discomfort is persistent and frequently difficult to treat. It is due, at least partly, to changes in molecular signalling occasions that take place in neurons, alterations that may ultimately disrupt the transmitting of nerve indicators from the spinal cord to the mind. We have been fortunate to possess a wide range of technologies that allow us to look more precisely at the molecular events that lead to the onset of persistent pain in animals, said Marc Landry, lead author of the analysis and Professor at the University of Bordeaux.